Reasoning about the physical world enables people to successfully interact with and manipulate their environment. In this Review, Hartshorne and Jing bridge findings from education, developmental psychology and cognitive science and discuss how best to reconcile these approaches going forward.
A newly identified part of a brain circuit mixes sensory information, memories, and emotions to tell whether things are familiar or new, and important or just “background noise.”
Led by researchers from NYU Langone Health, the work found that a circuit known to carry messages from a brain region that processes sensory information, the entorhinal cortex (EC), to the memory processing center in the hippocampus (HC) has a previously unrecognized pathway that carries messages directly back to the EC.
Publishing online Feb. 18 in Nature Neuroscience, the study results show that this direct feedback loop sends signals fast enough to instantly tag sights and sounds linked to certain objects and places as more important by considering them in the context of memories and emotions.
Shen et al. investigate the use of Lactobacillus plantarum, a commensal bacterial strain, as a chassis for targeting the olfactory mucosa to facilitate precise nose-to-brain delivery of therapeutic molecules. When engineered to secrete appetite-regulating hormones, intranasal delivery of L. plantarum alleviates obesity-related symptoms in a mouse model.
“Can you hand me the… you know… the thingy? It’s right there next to that other doohickey!” Struggling to find the right word happens to all of us. In fact, it even has a name; lethologica, and it tends to become more common as we get older.
Forgetting words now and then isn’t a big deal, but if it starts happening frequently, it could be an early sign of changes in the brain linked to Alzheimer’s disease —long before more obvious symptoms appear. But here’s the twist: A recent University of Toronto study suggests that how fast you speak might be a better clue about brain health than the occasional word mix-up.
Posted in neuroscience | Leave a Comment on Nasal anti-CD3 monoclonal antibody ameliorates traumatic brain injury, enhances microglial phagocytosis and reduces neuroinflammation via IL-10-dependent Treg–microglia crosstalk Neuroscience
Nasal anti-CD3 therapy shows promise for treating traumatic brain injury by reducing neuroinflammation and aiding recovery in mice. It induces interleukin-10-producing regulatory T cells that enhance microglial phagocytic activity and reduce chronic inflammation, potentially aiding brain repair.
Could your driving habits reveal your mental health? Research shows AI can analyze driving data to identify depression risk in older adults.
Get a Wonderful Person Tee: https://teespring.com/stores/whatdamathMore cool designs are on Amazon: https://amzn.to/3QFIrFXAlternatively, PayPal donations ca…
Biomedical engineers at the University of Melbourne have developed a 3D bioprinting system capable of creating structures that closely replicate various human tissues, ranging from soft brain tissue to more rigid materials like cartilage and bone.
This innovative technology provides cancer researchers with a powerful tool for replicating specific organs and tissues, enhancing their ability to predict drug responses and develop new treatments. By offering a more accurate and ethical approach to drug discovery, it also has the potential to reduce reliance on animal testing.
Head of the Collins BioMicrosystems Laboratory at the University of Melbourne, Associate Professor David Collins said: In addition to drastically improving print speed, our approach enables a degree of cell positioning within printed tissues. Incorrect cell positioning is a big reason most 3D bioprinters fail to produce structures that accurately represent human tissue.
New data on brain-wide circuits centred around two interconnected hypothalamic neuron populations provide significant mechanistic insights into the emergence of social need during social isolation and the satiation of social need during social reunion.
Scientists at the La Jolla Institute for Immunology (LJI) have identified a potential new target for Parkinson’s disease treatment. Their research highlights the role of a specific brain cell protein in triggering the disease and may explain why Parkinson’s is more prevalent in men.
Recent studies from LJI suggest that autoimmunity plays a key role in Parkinson’s onset. Their latest findings, published in The Journal of Clinical Investigation, reveal that the protein PINK1 may label certain brain cells for attack by the immune system, contributing to disease progression.
“This research allows us to better understand the role of the immune system in Parkinson’s disease,” says LJI Professor Alessandro Sette, Dr. Biol. Sci., senior author of the recent study.
